Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT03999684 Completed - Clinical trials for Adenoid Cystic Carcinoma

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Start date: August 5, 2019
Phase: Phase 2
Study type: Interventional

This research is studying how safe and effective all-trans retinoic acid (ATRA), is to treat advanced adenoid cystic carcinoma (ACC).

NCT ID: NCT03990571 Completed - Progressive Disease Clinical Trials

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Start date: July 22, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.

NCT ID: NCT03989297 Completed - Clinical trials for Nasopharyngeal Carcinoma

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Start date: January 1, 2017
Phase:
Study type: Observational

The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

NCT ID: NCT03988959 Completed - Clinical trials for Adenocarcinoma; Mucoepidermoid Carcinoma

Surgical Management of Multiple Mucoepidermoid Carcinoma and Adenocarcinoma

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

A case series of patient having mucoepidermoid carcinoma, had standard treatment protocol and surgeries and followup was performed and the patient postoperative quality of life and recurrent rate was recorded

NCT ID: NCT03985046 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Start date: October 10, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT03982407 Completed - Clinical trials for Hepatocellular Carcinoma

68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

Start date: June 27, 2019
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to investigate the evaluate to use of a drug/radiopharmaceutical called Gallium-68 PSMA-11 (68Ga-PSMA-11) for use in PET/MRI evaluation of hepatocellular carcinoma

NCT ID: NCT03981224 Completed - Clinical trials for Nasopharyngeal Carcinoma

The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients

Start date: May 2, 2012
Phase:
Study type: Observational

An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should strengthen adjuvant therapy due to very high subsequent relapse rate and poor survivals.

NCT ID: NCT03980288 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Start date: July 23, 2019
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of 4th generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma

NCT ID: NCT03980041 Completed - Bladder Cancer Clinical Trials

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Start date: September 25, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.

NCT ID: NCT03973723 Completed - Clinical trials for Nasopharyngeal Carcinoma

Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Start date: August 1, 2011
Phase:
Study type: Observational

Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.